Christiane Mendre

Montpellier, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Inactive structures of the vasopressin V2 receptor reveal distinct binding modes for Tolvaptan and Mambaquaretin toxin.

Inactive structures of the vasopressin V2 receptor reveal distinct binding modes for Tolvaptan and Mambaquaretin toxin.

Journal: Nature communications

Published: November 15, 2024

Biased activation of the vasopressin V2 receptor probed by molecular dynamics simulations, NMR and pharmacological studies.

Biased activation of the vasopressin V2 receptor probed by molecular dynamics simulations, NMR and pharmacological studies.

Journal: Computational and structural biotechnology journal

Published: July 15, 2024

A Snake Toxin Derivative for Treatment of Hyponatremia and Polycystic Kidney Diseases.

A Snake Toxin Derivative for Treatment of Hyponatremia and Polycystic Kidney Diseases.

Journal: Journal of the American Society of Nephrology : JASN

Published: May 01, 2024

Characterization of a functional V1B vasopressin receptor in the male rat kidney: evidence for cross talk between V1B and V2 receptor signaling pathways.

Characterization of a functional V1B vasopressin receptor in the male rat kidney: evidence for cross talk between V1B and V2 receptor signaling pathways.

Journal: American journal of physiology. Renal physiology

Published: July 20, 2021

A new Kunitz-type snake toxin family associated with an original mode of interaction with the vasopressin 2 receptor.

A new Kunitz-type snake toxin family associated with an original mode of interaction with the vasopressin 2 receptor.

Journal: British journal of pharmacology

Published: July 01, 2021

A snake toxin as a theranostic agent for the type 2 vasopressin receptor.

A snake toxin as a theranostic agent for the type 2 vasopressin receptor.

Journal: Theranostics

Published: April 27, 2020

Misfolding of vasopressin receptors: biased agonist pharmacochaperones as potential therapeutics.

Misfolding of vasopressin receptors: biased agonist pharmacochaperones as potential therapeutics.

Journal: Advances in protein chemistry and structural biology

Published: January 14, 2020

Pharmacological Chaperones as Potential Therapeutic Strategies for Misfolded Mutant Vasopressin Receptors.

Pharmacological Chaperones as Potential Therapeutic Strategies for Misfolded Mutant Vasopressin Receptors.

Journal: Handbook of experimental pharmacology

Published: September 24, 2017

Green mamba peptide targets type-2 vasopressin receptor against polycystic kidney disease.

Green mamba peptide targets type-2 vasopressin receptor against polycystic kidney disease.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: June 21, 2017

V1b vasopressin receptor trafficking and signaling: Role of arrestins, G proteins and Src kinase.

V1b vasopressin receptor trafficking and signaling: Role of arrestins, G proteins and Src kinase.

Journal: Traffic (Copenhagen, Denmark)

Published: August 01, 2016

Red fluorescent turn-on ligands for imaging and quantifying G protein-coupled receptors in living cells.

Red fluorescent turn-on ligands for imaging and quantifying G protein-coupled receptors in living cells.

Journal: Chembiochem : a European journal of chemical biology

Published: October 24, 2013

Vasopressin receptors and pharmacological chaperones: from functional rescue to promising therapeutic strategies.

Vasopressin receptors and pharmacological chaperones: from functional rescue to promising therapeutic strategies.

Journal: Pharmacological research

Published: October 06, 2013

Showing 1-12 of 13

Last Updated: 09/26/2026